Akebia Therapeutics Inc.’s recently made public that its CEO and President Butler John P. unloaded Company’s shares for reported $73581.0 on Feb 29 ’24. In the deal valued at $1.58 per share,46,570 shares were sold. As a result of this transaction, Butler John P. now holds 2,044,580 shares worth roughly $4.44 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dahan Michel sold 8,661 shares, generating $13,684 in total proceeds. Upon selling the shares at $1.58, the SVP, Chief Operating Officer now owns 706,932 shares.
Before that, Burke Steven Keith sold 7,169 shares. Akebia Therapeutics Inc. shares valued at $11,327 were divested by the SVP, Chief Medical Officer at a price of $1.58 per share. As a result of the transaction, Burke Steven Keith now holds 695,840 shares, worth roughly $1.51 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “a Buy”. Piper Sandler also remained covering AKBA and has increased its forecast on May 31, 2023 with a “an Overweight” recommendation from previously “Neutral” rating. Piper Sandler revised its rating on March 31, 2022. It rated AKBA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of AKBA
On Friday, Akebia Therapeutics Inc. [NASDAQ:AKBA] saw its stock jump 6.37% to $2.17. Over the last five days, the stock has gained 27.65%. Akebia Therapeutics Inc. shares have risen nearly 75.00% since the year began. Nevertheless, the stocks have risen 225.09% over the past one year. While a 52-week high of $2.08 was reached on 03/22/24, a 52-week low of $0.49 was recorded on 01/02/24. SMA at 50 days reached $1.58, while 200 days put it at $1.27. A total of 7.85 million shares were traded, compared to the trading of 6.56 million shares in the previous session.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 2.05, which if violated will result in even more drops to 1.92. On the upside, there is a resistance level at 2.27. A further resistance level may holdings at 2.36. The Relative Strength Index (RSI) on the 14-day chart is 73.51, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 7.78%. Stochastics %K at 90.44% indicates the stock is a selling.
How much short interest is there in Akebia Therapeutics Inc.?
A steep rise in short interest was recorded in Akebia Therapeutics Inc. stocks on Feb 29, 2024, dropping by -0.67 million shares to a total of 8.11 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 8.78 million shares. There was a decline of -8.26%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.36% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.69.
